Profile data is unavailable for this security.
About the company
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis and uterine fibroids; Nolasiban (OBE001), an oral oxytocin receptor antagonist, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor.
- Revenue in CHF (TTM)13.54m
- Net income in CHF7.25m
- Incorporated2012
- Employees15.00
- LocationObseva SAChemin des Aulx 12PLAN-LES-OUATES 1228SwitzerlandCHE
- Phone+41 225521558
- Websitehttps://www.obseva.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| European Institute of Science AB | 50.27k | -227.55k | 431.39k | 0.00 | -- | 1.28 | -- | 8.58 | -4.25 | -4.25 | 0.9397 | 2.98 | 0.1728 | 0.8479 | 8.63 | -- | -78.21 | -93.04 | -82.77 | -103.14 | 62.33 | 67.01 | -452.67 | -518.82 | 10.54 | -- | -- | -- | 13.69 | 8.54 | 0.4062 | -- | -- | -- |
| MediNavi AG | -98.07bn | -98.07bn | 473.92k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Bio Vitos Pharma AB | 250.00k | -1.08m | 518.27k | 1.00 | -- | 1.61 | 12.05 | 2.07 | -0.2547 | -0.2547 | 0.0533 | 0.1119 | 0.0989 | 0.00 | 5.38 | 2,983,990.00 | -42.63 | -31.11 | -44.50 | -32.92 | 100.00 | -- | -431.21 | -1,026.76 | 4.27 | -- | 0.00 | -- | 126.97 | -- | 13.64 | -- | -- | -- |
| Eurocine Vaccines AB | 419.00 | -1.26m | 553.09k | 3.00 | -- | -- | -- | 1,320.33 | -0.1472 | -0.1472 | 0.00005 | -0.0018 | 0.0007 | -- | 0.002 | -- | -199.76 | -83.17 | -323.19 | -97.89 | -199,780.00 | -- | -301,180.00 | -- | -- | -- | -- | -- | -- | -- | 8.95 | -- | -- | -- |
| CoDon AG | 9.65m | -13.85m | 592.66k | 134.00 | -- | 0.0912 | -- | 0.0614 | -0.5513 | -0.5513 | 0.4018 | 0.2468 | 0.5161 | 0.9864 | 10.10 | 73,432.84 | -74.08 | -41.86 | -86.85 | -48.53 | 94.10 | 91.39 | -143.53 | -139.57 | 0.8393 | -21.92 | 0.4887 | -- | 57.28 | 11.86 | 32.79 | -- | 24.07 | -- |
| Lipidor AB | 6.45k | -962.30k | 594.78k | -- | -- | -- | -- | 92.20 | -0.3964 | -0.3964 | 0.0027 | -0.3223 | 0.0084 | -- | 5.31 | -- | -124.54 | -59.41 | -- | -75.10 | -- | -- | -14,916.88 | -643.36 | -- | -- | -- | -- | 73.33 | -20.33 | 72.24 | -- | -- | -- |
| QuiaPEG Pharmaceuticals Holding AB | 0.00 | -1.38m | 602.93k | 8.00 | -- | 0.4719 | -- | -- | -3.51 | -3.51 | 0.00 | 0.2047 | 0.00 | -- | -- | -- | -50.53 | -95.67 | -100.54 | -207.86 | -- | 262.59 | -- | -5,002.50 | -- | -15.34 | 0.00 | -- | -- | -- | 17.75 | -- | 47.06 | -- |
| Stayble Therapeutics AB | 0.00 | -1.99m | 608.59k | 3.00 | -- | 0.44 | -- | -- | -0.9492 | -0.9492 | 0.00 | 0.5204 | 0.00 | -- | -- | 0.00 | -116.21 | -78.64 | -141.76 | -95.58 | -- | -- | -- | -- | -- | -- | 0.049 | -- | -- | -- | 3.22 | -- | -- | -- |
| 2cureX AB | 12.99k | -2.58m | 672.50k | -- | -- | 0.5863 | -- | 51.79 | -1.75 | -1.75 | 0.0088 | 0.7777 | 0.0048 | -- | 0.0838 | -- | -95.89 | -38.21 | -108.66 | -43.48 | -6,889.68 | -22,153.06 | -19,883.23 | -38,685.30 | -- | -46.08 | -- | -- | 72.22 | -- | -3.52 | -- | -- | -- |
| Ovoca Bio PLC | 0.00 | -2.29m | 702.56k | 5.00 | -- | 0.1417 | -- | -- | -0.0245 | -0.0245 | 0.00 | 0.053 | 0.00 | -- | -- | 0.00 | -27.00 | -17.82 | -32.86 | -19.39 | -- | -- | -- | -- | 4.68 | -48.64 | 0.00 | -- | -- | -- | -6.96 | -- | -- | -- |
| Obseva SA | 13.54m | 7.25m | 721.26k | 15.00 | 0.1053 | 0.2625 | 0.0993 | 0.0533 | 0.0605 | 0.0605 | 0.1287 | 0.0243 | 0.4682 | -- | 108.39 | 902,889.60 | 25.07 | -73.61 | 37.56 | -90.70 | -- | -- | 53.55 | -838.80 | -- | -- | 0.1957 | -- | -11.55 | 314.75 | 43.60 | -- | -- | -- |
| Voyager Life PLC | 360.15k | -1.26m | 722.74k | 28.00 | -- | 0.9933 | -- | 2.01 | -0.0912 | -0.0912 | 0.0253 | 0.044 | 0.1897 | 1.58 | 3.85 | 11,214.29 | -66.51 | -- | -77.02 | -- | 41.72 | -- | -350.64 | -- | 2.83 | -69.50 | 0.4625 | -- | 59.55 | -- | -38.70 | -- | -- | -- |
| Oxurion NV | 257.92k | -18.60m | 884.08k | 20.00 | -- | -- | -- | 3.43 | -0.023 | -0.023 | 0.0002 | -0.0038 | 0.0284 | 63.60 | 0.1253 | 13,150.00 | -204.59 | -84.30 | -- | -118.70 | 39.54 | 48.90 | -7,212.55 | -2,008.99 | 0.1398 | -1.75 | -- | -- | -55.80 | -45.20 | 40.13 | -- | -65.17 | -- |
| Amniotics AB (publ) | 0.00 | -2.59m | 893.00k | 6.00 | -- | 0.6803 | -- | -- | -0.0374 | -0.0374 | 0.00 | 0.0057 | 0.00 | -- | -- | 0.00 | -112.25 | -101.09 | -362.71 | -149.92 | -- | -- | -- | -- | 1.12 | -16.17 | -- | -- | -- | -- | 35.75 | -- | -- | -- |
Data as of May 02 2024. Currency figures normalised to Obseva SA's reporting currency: Swiss Franc CHF
3.46%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| JGB Capital Management LPas of 24 Feb 2023 | 2.09m | 1.43% |
| Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 1.29m | 0.88% |
| Z�rcher Kantonalbank (Investment Management)as of 29 Feb 2024 | 668.49k | 0.46% |
| UBS Asset Management Switzerland AGas of 02 Apr 2024 | 602.53k | 0.41% |
| BlackRock Asset Management Schweiz AGas of 04 Apr 2024 | 199.94k | 0.14% |
| Pictet Asset Management SAas of 31 Dec 2023 | 170.67k | 0.12% |
| DWS CH AGas of 29 Feb 2024 | 30.69k | 0.02% |
| CATAM Asset Management AGas of 29 Feb 2024 | 10.00k | 0.01% |
| State Street Global Advisors France SAas of 31 Dec 2023 | 4.50k | 0.00% |
| LLB Asset Management AGas of 29 Feb 2024 | 3.91k | 0.00% |
More ▼
Data from 24 Feb 2023 - 25 Apr 2024Source: FactSet Research Systems Inc.
